By using a whole-proteome microarray measuring 199-marker anti-EBV peptide sequences from 86 EBV proteins, 14 NPC-specific EBV markers have recently been identified, which showed ∼10% improvement in the accuracy rate for predicting NPC onset compared with VCA and EBNA1 IgA alone, which have been used in conventional NPC screening programmes.22 The gene discussed is CD79A; the disease is nasopharyngeal carcinoma.